Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase 2

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: LNP023

First Posted Date: 2019-03-29

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT03896152

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Phase 1

Active, not recruiting

Conditions: Nasopharyngeal Carcinoma
Microsatellite Stable Colorectal Cancer
Carcinoma, Non-Small-Cell Lung
Melanoma
Triple Negative Breast Cancer

Interventions: Drug: DKY709
Drug: PDR001

First Posted Date: 2019-03-27

Last Posted Date: 2025-01-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 99

Registration Number: NCT03891953

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 1 locations

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Not Applicable

Completed

Conditions: Cardiovascular Disease and Lipoprotein(a)

Interventions: Diagnostic Test: Blood draw for Lp(a)

First Posted Date: 2019-03-25

Last Posted Date: 2022-01-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49001

Registration Number: NCT03887520

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Phase 2

Active, not recruiting

Conditions: B-Cell Acute Lymphoblastic Leukemia

Interventions: Biological: CTL019

First Posted Date: 2019-03-15

Last Posted Date: 2024-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 121

Registration Number: NCT03876769

Locations: 🇺🇸
Dana Farber Cancer Institute Dept.of DFCI, Boston, Massachusetts, United States
🇺🇸
Methodist Childrens Hospital ., San Antonio, Texas, United States
🇺🇸
City of Hope National Medical, Duarte, California, United States

and more 30 locations

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Phase 1

Terminated

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Biological: Tisagenlecleucel
Drug: Ibrutinib

First Posted Date: 2019-03-15

Last Posted Date: 2023-01-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT03876028

Locations: 🇺🇸
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Nilotinib
Drug: Asciminib

First Posted Date: 2019-03-14

Last Posted Date: 2024-11-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 124

Registration Number: NCT03874858

Locations: 🇮🇹
Novartis Investigative Site, Novara, Italy

Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

Phase 3

Active, not recruiting

Conditions: Migraine

Interventions: Other: Placebo
Biological: Erenumab

First Posted Date: 2019-03-07

Last Posted Date: 2024-04-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 557

Registration Number: NCT03867201

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Phase 3

Completed

Conditions: Homozygous Familial Hypercholesterolemia

Interventions: Drug: Inclisiran Sodium for injection
Drug: Placebo
Drug: Placebos

First Posted Date: 2019-02-22

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT03851705

Locations: 🇷🇺
(50007-001) Research Institute of Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
🇷🇸
(50381-001) Clinical Center of Serbia, Belgrad, Serbia
🇹🇷
(50090-001) Ege Universitesi, İzmir, Turkey

and more 10 locations

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Combination Product: Docetaxel / Capecitabine
Drug: Letrozole OR Anastrozole
Combination Product: Capecitabine / Vinorelbine
Combination Product: Paclitaxel / Gemcitabine
Drug: Goserelin

First Posted Date: 2019-02-15

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 223

Registration Number: NCT03839823

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Phase 2

Completed

Conditions: Glomerulonephritis

Interventions: Drug: LNP023

First Posted Date: 2019-02-06

Last Posted Date: 2024-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT03832114

Locations: 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy